SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Bhag Karamchandani who wrote (4181)4/29/1998 10:09:00 PM
From: billkirn  Read Replies (2) | Respond to of 6136
 
AG3340: Not sure if any comparison is published but a short conversation with Mr. Quart, last year, where he indicated AG3340 has almost no side effects as determined at that time. He felt AG3340 was a very much better MMP inhibitor and that BB's MMP was somewhat troublesome. Not sure what that means, but sounded positive. He also felt they would beat the 2000 time frame for NDA. I had a feeling he had some kind of information he could not share about a speedy process to get it on the market.
Bill



To: Bhag Karamchandani who wrote (4181)4/29/1998 10:39:00 PM
From: Henry Niman  Respond to of 6136
 
I uploaded the entire table. I think that the compounds in the table were fairly advanced, with NDAs already filed or to be filed by early 1999. The list was not for all Phase III compounds - just those that would likely lead to product launches soon (by 1999?).


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News